BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LMT503 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LMT503\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05659953-68@assetmemo.bio
DTSTAMP:20261121T004452Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:LMT503: Phase 1 readout est. (NCT05659953)
DESCRIPTION:LMT503\, phase 1\, Ulcerative Colitis.\nStudy: LMT503 First-in-
 human SAD\, MAD\, and FE Study\nEstimated primary completion: 1 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lmt503#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05659953
URL:https://assetmemo.bio/drug/lmt503#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
